changing the labeling to refl ect approval for use in patients receiving palliative care but not those being treated with curative intent.
"For patients receiving cancer treatment that has the potential for cure, ESAs ' risk may undermine this therapeutic goal," said Richard Pazdur, M.D., head of the offi ce of oncology drug products at the FDA, at a press meeting. "The risk -benefi t balance is a delicate one and may be different for patients receiving palliative care."
The new rules, which apply to Amgen's Epogen and Procrit (both epoetin alfa) and to Aranesp (darbepoetin alfa), stipulate that the FDA will allow only physicians who register for the program, certify that they have received training, and sign off that they have discussed the risks with patients each time to prescribe and dispense ESAs. Physicians must reenroll every 3 years. Patients must receive a medication guide explaining risks and benefi ts of the drugs and sign an informed-consent form.
" 
Dueling Studies
With the FDA's position on ESAs fully articulated and fi nal, one might assume that any remaining debate would end. But Amgen still refutes the fi ndings that ESAs shorten lifespans and induce cancer growth, and the company intends to prove so in clinical trials.
Amgen published two studies in the February issue of Blood , which, according to the company, demonstrate that no functional EPO receptors exist on four cell types and in human tumor cell lines. (The existence of such receptors, which other researchers have found, indicates a possible mechanism for ESAs to cause cancer growth.) "Based on a comprehensive analysis of the evidence in numerous preclinical and clinical studies, Amgen believes there is no defi nitive evidence of EPO receptor involvement in tumor progression, and no reliable evidence that functional EPO receptors are present on cancer cells or associated vasculature," said an Amgen spokesperson in an e-mail.
Laurie Feldman, Ph.D., assistant professor of medicine at Harvard University, whose research, with Sytkowski's, shows functional EPO receptors on ovarian, prostate, and breast cancer cells, believes that differences in the specifi city of antibodies used to detect the receptors may partly explain the discrepancies. But she and others have not been able to access Amgen's antibodies to independently verify its results.
"Amgen has also stated that its inability to demonstrate specifi c binding of radiolabeled EPO to cancer cells shows that there are no EPO receptors on these cells. But the big thing is why different labs see different things with the same cells," Feldman said.
She observed that no standardized, commonly available reagents, assays, and cell lines exist that researchers use, a problem FDA flagged in 2007 and 2008 at the National Institutes of Healthsponsored workshops. But with no movement on that front, these questions probably will not be resolved to Amgen's satisfaction. As for the FDA, the case in cancer is closed, and it has now moved on to investigating risks of ESAs in kidney failure.
